Progress in PKMYT1 Inhibition: RP-6306

Time: 1:30 pm
day: Day Two

Details:

  • Exploring the drug discovery process: target identification and validation, antitumor effect, pathway understanding, biomarkers
  • Discussing potential indications?
  • Forecasting the future of PKMYT1 to be monotherapy and/or combination dominated
  • Sequencing dose schedule hypothesis?
  • Latest data and future directions

Speakers: